Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~A volunteer must meet all of the following criteria:~* Able and willing to complete the informed consent process.~* Available for clinical follow-up through the last study visit.~* 18 to 60 years of age.~* In good general health without clinically significant medical history.~* Willing to have blood samples collected, stored indefinitely, and used for research purposes.~* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.~* Physical examination without clinically significant findings within the 84 days prior to enrollment.~* Have screening laboratory values within 84 days prior to enrollment that meet the following criteria:~  * White Blood Cell (WBC) 2,500-12,000/mm\^3~ * WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval~ * Platelets = 125,000 - 400,000/mm\^3~ * Hemoglobin within institutional normal range or accompanied by the PI or designee approval~ * Creatinine less than or equal to 1.1 x upper limit of normal (ULN)~ * Alanine aminotransferase (ALT) less than or equal to 1.25 x ULN~ * Negative for human immunodeficiency virus (HIV) infection by a Food and Drug Administration (FDA) approved method of detection~ * Negative for Hepatitis B core antibody (HBcAb) and Hepatitis C virus antibody (HCV Ab)~* Criteria applicable to women of childbearing potential:~  * If a woman is of reproductive potential and sexually active with a male partner, then she agrees to use an effective means of birth control from the time of study enrollment until the last study visit, or to be monogamous with a partner who has had a vasectomy.~ * Negative human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on day of enrollment and product administration.~EXCLUSION CRITERIA:~A volunteer will be excluded from study participation if one or more of the following conditions apply:~* Previous receipt of a licensed or investigational monoclonal antibody or Ebola vaccine.~* Weight \>100 kg.~* Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the study.~* Hypertension that is not well controlled.~* Woman who is breast-feeding, or planning to become pregnant during study participation.~* Receipt of any investigational study product within 28 days prior to enrollment.~* Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer.~* Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular (IM) injections or blood draws.~* Use of angiotensin-converting enzyme (ACE) inhibitors or other potential nephrotoxins.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: 5 mg/kg IV (Type: EXPERIMENTAL): Group 1 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5 mg/kg.
- Group 2: 25 mg/kg IV (Type: EXPERIMENTAL): Group 2 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25 mg/kg.
- Group 3: 50 mg/kg IV (Type: EXPERIMENTAL): Group 3 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete